A, P., C, T., J, L., C, H., D, C., L, K., . . . P, M. (2025). Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: Analysis of the MIDAS trial. Blood, 146(1), 52. https://doi.org/10.1182/blood.2024026230
Chicago Style (17th ed.) CitationA, Perrot, et al. "Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial." Blood 146, no. 1 (2025): 52. https://doi.org/10.1182/blood.2024026230.
MLA (9th ed.) CitationA, Perrot, et al. "Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial." Blood, vol. 146, no. 1, 2025, p. 52, https://doi.org/10.1182/blood.2024026230.
Warning: These citations may not always be 100% accurate.
